1-3 of 3
Horst Lindhofer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study

Free
Markus M. Heiss, Michael A. Ströhlein, Carsten Bokemeyer, Dirk Arnold, Simon L. Parsons, Diane Seimetz, Horst Lindhofer, Elisabeth Schulze, Michael Hennig
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3348–3357.
https://doi.org/10.1158/1078-0432.CCR-13-2351
Published: 12 June 2014
View articletitled, The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
Open the PDF for The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study in another window
Journal Articles

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Free
Alexander Burges, Pauline Wimberger, Carolin Kümper, Vera Gorbounova, Harald Sommer, Barbara Schmalfeldt, Jacobus Pfisterer, Michail Lichinitser, Anatoliy Makhson, Vladimir Moiseyenko, Angelika Lahr, Elisabeth Schulze, Michael Jäger, Michael A. Ströhlein, Markus Maria Heiss, Thomas Gottwald, Horst Lindhofer, Rainer Kimmig
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3899–3905.
https://doi.org/10.1158/1078-0432.CCR-06-2769
Published: 02 July 2007
View articletitled, Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study
Open the PDF for Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study in another window
Journal Articles

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Free
Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert, Maja Heinrigs, Brigitte Rack, Alexander Marmé, Agnieszka Korfel, Michael Jäger, Horst Lindhofer, Harald Sommer, Eckhard Thiel, Michael Untch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3085–3091.
https://doi.org/10.1158/1078-0432.CCR-05-2436
Published: 17 May 2006
View articletitled, Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Open the PDF for Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer in another window